Luis Angel Hernandez Zarate

Luis Angel Hernandez Zarate

Auto-generated profile, based on publicly available information

Luis Angel Hernandez Zarate

Hospital Infantil de México Federico Gómez México City Mexico

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025
Verified
Journal Article
Open access
PDF file
LHLuis Angel Hernández-Zárate
Luis Angel Hernández-Zárate
CGCarlos Andrés Gómez-Núñez
Carlos Andrés Gómez-Núñez
SNStefan Narváez-Labuhn
Stefan Narváez-Labuhn
GMGerardo Morales-Velázquez
Gerardo Morales-Velázquez
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder affecting millions worldwide, with significant variations in clinical presentation influenced by socioeconomic, racial, and environmental factors. This review explores the current understanding of AD pathophysiology, emphasizing immune dysregulation, epithelial barrier dysfunction, and the role of cytokines, particularly interleukin (IL)-4 and IL-13, in disease progression. Safety and efficacy concerns limit traditional corticosteroids, phototherapy, and systemic immunosuppressants, prompting interest in innovative therapies. New biologic agents, including monoclonal antibodies (mAbs) and Janus kinase (JAK) inhibitors (JAKis), target specific immune pathways, promising outcomes in moderate-to-severe AD cases. Biologics like dupilumab and emerging JAKis have shown substantial efficacy and safety in clinical trials, with notable reductions in inflammation and pruritus. However, these advancements present challenges, including hypersensitivity risks and the high costs of biologics, underscoring the need for further research on long-term safety and accessibility. The shift toward precision medicine in AD management marks a significant evolution, with future approaches likely to integrate targeted therapies alongside multidisciplinary care to enhance patient outcomes and quality of life (QoL).

15 February 2026 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
ZMZaira Selene Mojica‐González
Zaira Selene Mojica‐González
JPJimena Prieto‐Gómez
Jimena Prieto‐Gómez
RMRicardo Martinez‐Tenopala
Ricardo Martinez‐Tenopala
THTamara Hernández‐Hernández
Tamara Hernández‐Hernández
LHLuis Ángel Hernández‐Zárate
Luis Ángel Hernández‐Zárate
Background: Children with asthma living in highly polluted megacities are at increased risk of poor asthma control and airway inflammation. Breastfeeding has immunomodulatory effects, but its potential to buffer pollution‐related inflammation remains understudied. Objective: To evaluate whether breastfeeding duration is associated with asthma control and airway eosinophilic inflammation (FeNO), and whether it modifies the impact of urban air pollution in children with asthma living in Mexico City. Methods: We conducted a multicenter retrospective study (2022–2025) including children aged 6–17 years with physician‐diagnosed asthma. Asthma control (ACT), airway inflammation (FeNO, NIOX VERO), breastfeeding duration (0–12 months), and borough‐level pollution categories (high/medium/low) were evaluated. Multivariable logistic and linear regression models assessed associations and breastfeeding × pollution interactions. Results: A total of 162 children were included (mean age 10.8 years; 51.2% female). Breastfeeding ≥ 6 months was associated with better asthma control (ACT ≥ 20: OR 2.1; 95% CI 1.3–3.5) and significantly lower FeNO (β −0.24; p < 0.01). High‐pollution residence was linked to lower ACT scores and higher FeNO (both p < 0.01). A significant interaction indicated that breastfeeding ≥ 6 months attenuated the detrimental effect of pollution on airway inflammation and asthma control ( p for interaction < 0.05). Conclusions: Prolonged breastfeeding was independently associated with improved asthma control and reduced airway eosinophilic inflammation, partially mitigating the respiratory burden of chronic pollution exposure. Clinical Implications: Breastfeeding may serve as an accessible, low‐cost protective strategy for children with asthma living in polluted urban environments, supporting its integration into respiratory health policies and early‐life preventive care.

21 June 2024
Verified
Preprint
Open access
PDF file
LALuis Eduardo Romero Garcia de Acevedo
Luis Eduardo Romero Garcia de Acevedo
MGMaría José del Rosario González Guerra
María José del Rosario González Guerra
YLYanni Alexis Torres Limon
Yanni Alexis Torres Limon
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
LZLuis Angel Hernandez Zarate
Luis Angel Hernandez Zarate
Background Respiratory allergic diseases such as asthma, chronic rhinosinusitis (CRS), and allergic rhinitis (AR), are complex multifactorial conditions influenced by genetic background, immune defenses, infection, antibiotic use, bacterial airway exposure, nutritional factors, environmental factors, and their involvement with the microbiota. Allergic respiratory diseases are characterized by the differentiation of Th0 into Th2, Th9, and Th17. An abnormal change in the microbiota will induce dysbiosis and an increase in the Th2 response, leading to respiratory allergic diseases. Objectives The objective is to explore the relationship between microbiota and allergic respiratory diseases, unraveling interactions between microbial communities and the immune system, and provide the physiopathology, development, prevention, and management of allergic respiratory conditions, paving the way for potential personalized therapeutic interventions. Methods This review aims to synthesize research about the microbiota in respiratory allergic diseases and how microbiome eubiosis can help in preventing respiratory allergic diseases. A systematic investigation was carried out, which included literature such as articles from PubMed, Elsevier, and Google Academics databases. Major Findings Different treatments have been implemented, such as the MedDiet suppressing PGE2, less proinflammatory cytokines, and Lactobacilli, Faecalibacterium, and Bifidobacteria colonization. Corticosteroids, probiotics, prebiotics, synbiotics, short-chain fatty acids, and the use of monoclonal antibody therapies showed an increment in immune tolerance. Implication Adjuvant treatments such as monoclonal therapy, MedDiet, probiotics, prebiotics, and symbiotics have beneficial results in allergic respiratory diseases. Further clinical trials are needed to give more support to these outcomes.